Of 18 votes cast so far, The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base leads with 44%.
This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales is second on 33%, 11 points behind.
Everyone who has answered so far is voting from China.
The poll is still live and picked up a vote today.